The novel tau imaging reagent, [18F]N-methyl lansoprazole showed good brain uptake in healthy controls; however, its retention in brains with mild cognitive impairment/AD and progressive supranuclear palsy was low (Kramer et al., 2020). Here, MAPT is linked to Alzheimer disease.